VBI Vaccines to Present at The World Vaccine Congress

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
171
VBI Vaccines to Present at The World Vaccine Congress Europe 2017 in Barcelona

CAMBRIDGE, MASSACHUSETTS--(Marketwired - Oct. 11, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced that Adam Buckley, vice president of business development, will discuss VBI's enveloped virus-like particle (eVLP) platform, highlighting data from two of the company's vaccine programs, during a presentation at the World Vaccine Congress Europe held Oct. 10-12, 2017, in Barcelona.

During the presentation, Mr. Buckley will provide a synopsis of VBI's eVLP technology, including an overview of the positive interim data from the Phase I clinical study of VBI's cytomegalovirus (CMV) vaccine and new preclinical data on VBI-2501, the company's bivalent Zika vaccine candidate, which demonstrated neutralizing antibody responses benchmarked to levels of naturally acquired Zika immunity.

Event Details:

About CMV

CMV can cause serious disease in newborns when a mother is infected during pregnancy. Each year, approximately 5,000 U.S. infants will develop permanent problems due to CMV, which can include deafness, blindness, and developmental delays. CMV affects more live births than Down syndrome or fetal alcohol syndrome, making it a key public health priority and a strong candidate for recommended universal vaccination and reimbursement.

To learn more about CMV, visit: https://www.vbivaccines.com/cmv/

About Zika Virus

Zika is a flavivirus related to dengue, yellow fever, and West Nile. While the acute manifestations of Zika virus infection are typically mild, the disease has been associated with a number of neurological complications. There is scientific consensus that the Zika virus can cause congenital microcephaly, a condition where a child is born with a smaller than expected head due to abnormal brain development. Zika virus may also cause Guillain-Barrė syndrome ("GBS"), a disorder in which the body's immune system attacks the nerves, leading to muscle weakness or, in severe cases, paralysis.

Zika is spread primarily through the bite of an infected Aedes species mosquito, but some evidence suggests that it also may be transmitted sexually or during childbirth. In February 2016, the World Health Organization ("WHO") declared Zika a Public Health Emergency of International Concern ("PHEIC"), saying that the virus was "spreading explosively" in the Americas. There is currently no vaccine to prevent Zika infection.

To learn more about VBI's Zika Vaccine Program, visit: http://www.vbivaccines.com/zika/

About VBI Vaccines Inc.

VBI Vaccines Inc. ("VBI") is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI's first marketed product is Sci-B-Vac™, a hepatitis B (HBV) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI's eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (CMV) and glioblastoma multiforme (GBM). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that enables vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

Cautionary Statement on Forward-looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively "forward-looking statements"). The company cautions that such statements involve risks and uncertainties that may materially affect the company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the company, is set forth in the Company's filings with the Securities and Exchange Commission and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2017, and filed with the Canadian security authorities at sedar.com on March 24, 2017, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

VBI Contact Nicole Anderson Communications Executive Phone: (617) 830-3031 x124 Email: info@vbivaccines.com VBI Media Contact Matt Middleman, M.D. LifeSci Public Relations Phone: (646) 627-8384 Email: matt@lifescipublicrelations.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 172

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 134

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 154

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 71

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 118

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Lyft Upgraded to Buy: Insights for Future Growth Potential

Updated Category News Views 292

Lyft's Upgrade by Benchmark: A Closer Look Benchmark analysts have recently upgraded Lyft (NASDAQ: LYFT) from Hold to Buy, highlighting what's described as "significant optionality" for the rideshare company. This decision comes despite the heightened competition from major players like Tesla and Waymo, indicating confidence in Lyft's capability to navigate potential...

Continue Reading
LiveOne Board Changes Amid Expansion and Financial Growth

Updated Category News Views 120

LiveOne Announces Departure of Board Member LiveOne, Inc. (NASDAQ:LVO) has recently made headlines in the retail-eating sector with the announcement of Craig Foster's resignation from its board of directors. Foster, who also contributed to the Audit Committee and Nominating and Corporate Governance Committee, stepped down to focus on his other professional commitments....

Continue Reading
Concorde International Group's Remarkable 80% After-Hours Surge

Updated Category News Views 429

Concorde International Group's Stock Surge Explained Concorde International Group Ltd. (NASDAQ: CIGL) has captured attention in the stock market after experiencing an impressive 80.16% increase during after-hours trading, reaching a price of $4.63. Investors are buzzing and speculating about what led to this dramatic leap. Exciting New Equity Incentive Plan Announced The...

Continue Reading
Celebrating the Legacy of Dr. Iain Douglas-Hamilton

Updated Category News Views 301

Special Screenings of A Life Among Elephants In a remarkable celebration of conservation, special screenings of the inspiring film A Life Among Elephants will honor the legacy of Dr. Iain Douglas-Hamilton. This film encapsulates the essence of his lifelong dedication to elephant conservation, portraying not only the threats faced by these majestic creatures but also the...

Continue Reading
Saudi Arabia Launches Major SME Report at Biban24 Event

Updated Category News Views 75

Saudi Arabia Presents Key Economic Insights at Biban24 As Saudi Arabia continues its path toward achieving ambitious Vision 2030 objectives, Monsha'at, the authority dedicated to small and medium enterprises (SMEs), is hosting Biban24. This significant event, designed to promote entrepreneurship and growth opportunities, brings together global entrepreneurs and investors...

Continue Reading